Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity

Anthracyclines such as doxorubicin are highly effective chemotherapy agents used to treat many common malignancies. However, their use is limited by cardiotoxicity. We previously identified visnagin as protecting against doxorubicin toxicity in cardiac but not tumor cells. In this study, we sought t...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:JCI Insight
Κύριοι συγγραφείς: Asnani, Aarti, Zheng, Bahoui, Liu, Yan, Wang, You, Chen, Howard H., Vohra, Anita, Chi, An, Cornella-Taracido, Ivan, Wang, Huijun, Johns, Douglas G., Sosnovik, David E., Peterson, Randall T.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society for Clinical Investigation 2018
Θέματα:
Research Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5821184/
https://ncbi.nlm.nih.gov/pubmed/29321375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.96753
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια